BioCentury
ARTICLE | Clinical News

Seattle Genetics gains on Phase II mCRC data from Cascadian candidate

September 27, 2019 10:37 PM UTC

Newly released data showed Seattle Genetics’ tucatinib met the primary endpoint in the Phase II MOUNTAINEER trial for metastatic colorectal cancer, marking the first sign of fruit from its $614 million acquisition of Cascadian Therapeutics last year.

Data released in an abstract ahead of a presentation at the European Society for Medical Oncology (ESMO) meeting in Barcelona showed that among 22 evaluable HER2-amplified metastatic CRC patients, HER2 inhibitor tucatinib plus Herceptin trastuzumab led to a 55% overall response rate (ORR), as well as median progression-free and overall survival of 6.2 and 17.3 months, respectively...